To assess the role of hematopoietic SCT (HSCT) in adult ALL patients with central nervous system involvement at diagnosis, we retrospectively analyzed 90 patients who underwent autologous HSCT (auto-HSCT group; n ¼ 27) or allogeneic HSCT (allo-HSCT group; n ¼ 63) and reported to the Socié té Franc¸aise de Greffe de Moelle et de Thé rapie Cellulaire registry between 1994 and 2008. At the time of transplantation, 67 patients (74%) were in first CR, 15 (17%) in CRX2 and 8 (9%) with progressive disease. The 5-year probabilities of overall survival (OS) and disease-free survival (DFS) were 52% and 46% for the allo-HSCT and 37% and 33% for the auto-HSCT groups, respectively (P ¼ NS). The TRM at 5 years was 29.8% for the allo-HSCT group and 3.7% for the auto-HSCT group. Using univariate analysis, a time for transplantation of o12 months, the remission status at transplantation, the use of high-dose TBI and the number of the transplant were all determined to be prognostic factors for improved DFS and OS probabilities.
INTRODUCTION
Less than 10% of adult ALL have central nervous system (CNS) involvement at the time of diagnosis. 1, 2 Although the international ALL Medical Research Council (MRC) UKALL XII/Eastern Cooperative Oncology Group (ECOG) E2993 trial reported a worse outcome for ALL adults with CNS leukemia, the Leucé mies Aiguë s Lymphoblastiques de l 0 Adulte (LALA) trials and a Southwest Oncology Group study 1, 3 found no significant variation in survival according to CNS disease status. However, the outcome of CNS patient subgroups reported in the MRC trial was not statistically different in event-free survival (EFS) compared with other patients and the CNS subgroup of patients had a significantly high WBC count at diagnosis compared with CNS-negative ALL patients. Moreover, intensification by transplantation was more systematically used during the LALA trials in the CNS-positive subgroup of patients compared with the MRC/ECOG trial. In B-ALL, CNS involvement at the time of diagnosis did not adversely affect leukemia-free survival. 4, 5 For all these reasons the prognosis of CNS ALL patients remains controversial and is still debated.
Hematopoietic SCT (HSCT) is sometimes considered in this subgroup of patients because of the possible inferior outcome of disease. Autologous HSCT (auto-HSCT) has been proposed in the absence of a sibling donor. The outcome of HSCT in CNS ALL patients remains undefined. The goal of this study was to describe the outcome of 90 adults ALL patients with CNS disease treated with HSCT and reported to the Socié té Franc¸aise de Greffe de Moelle et de Thé rapie Cellulaire (SFGM-TC) registry.
MATERIALS AND METHODS
This was a retrospective, multi-center study assessing the results of allogeneic HSCT (allo-HSCT) or auto-HSCT in CNS ALL patients that reported to the SFGM-TC registry between 1994 and 2008. No selection criteria other than allo-HSCT or auto-HSCT for ALL patients aged X15 years and CNS involvement at the time of diagnosis were used. Patients were treated in 28 centers from 1994 to 2008. The study was approved by the scientific committee of the SFGM-TC. Information about the performance status, type of CNS involvement and DLI were unavailable for the majority of patients.
Statistical analysis
The data that were collected included age, sex, disease features, remission status at the time of transplant, transplant characteristics, GVHD status, disease-free survival (DFS) and OS. Survival duration was measured from the time of transplantation to either the time of death or last follow-up. We calculated DFS in patients who achieved a CR from the time of CR to either the time of relapse, death from any cause or last follow-up. TRM was defined as mortality exclusively related to the transplant. Patients' characteristics were compared using a w 
RESULTS

Patients' characteristics
The patients' disease and transplantation characteristics are summarized in Tables 1 and 2 . The median age was 27.8 years (range 17-63) and 23.7 years (range 15-57) for the auto-HSCT and allo-HSCT groups, respectively (P ¼ NS). The two groups were not different with respect to sex, ALL immunological classification, median WBC at diagnosis, organs involved, cytogenetics or molecular abnormalities. Eighty patients (91.1%) were in CR at the time of HSCT: 26 (96.3%) in the auto-HSCT group and 56 (88.9%) in the allo-HSCT group (P ¼ NS). Twenty-two patients received cerebral irradiation before transplant (12 in the allo-HSCT group versus 10 in auto-HSCT group, Po0.05). Two patients who relapsed after auto-HSCT were secondary allografted and three patients received a second allo-HSCT. The median time to transplantation was 6.4 months (range: 3.1-52.6) and 5.7 months (range: 2.7-73.1) for the auto-HSCT and allo-HSCT groups, respectively.
Allo-SCT procedure and donors' characteristics In the allo-HSCT group, 56 (89%) patients received myeloablative conditioning before transplant. This conditioning consisted of a TBI-based regimen for 51 patients (91%) and a BU-based regimen for 5 patients (9% GVHD and transplant morbidity Acute GVHD grades 3-4 occurred in 13 (20.7%) of the patients. Limited and extensive chronic GVHD were reported in 12 (19%) and 10 patients (15.8%), respectively ( Table 3) .
TRM at 5 years was 29.8% for the allo-HSCT group and 3.7% for the auto-HSCT group (P ¼ 0.02, Figure 1 ). Using univariate analysis, a first transplant, an auto-HSCT, remission status, early transplantation (o12 months post diagnosis) and female gender were significantly associated with reduced TRM. Table 4 summarizes the results of univariate analysis for TRM. Two independent factors were found to be predictive of TRM in post-HSCT patients using multivariable Cox regression models. The absence of remission before transplantation was associated with a worse TRM, represented by a hazard ratio (HR) ¼ 3.96 (95% confidence interval (CI) 1.09-14.41), P ¼ 0.036. Female gender was also an independent factor predicting worse TRM with an HR ¼ 3.26 (95% CI 1.19-8.86), P ¼ 0.021. Allo-HSCT was not an independent factor that predicted worse TRM (HR ¼ 6.23; 95% CI 0.8-48.3, P ¼ 0.08). Table 5 summarizes the results of a multivariable analysis for TRM. 
Survival
At 5 years, the probabilities of OS and DFS were 48% and 42% for the entire cohort, 52% and 37% for the allo-HSCT group and 46% and 33% for the auto-HSCT group, respectively (P ¼ NS, Figure 2 ). The locations of relapses were as follows: BM (n ¼ 11), CNS (n ¼ 1), BM and CNS (n ¼ 2), other sites (n ¼ 3) and unknown sites (n ¼ 16). Of the 17 relapsing patients in the allo-HSCT group, one isolated CNS relapse and one combined relapse (CNS and BM) occurred. One CNSisolated relapse occurred in the auto-HSCT group among 16 relapsing patients. The incidences of CNS relapse were 3.1% and 3.7% in the allo-HSCT and auto-HSCT groups, respectively.
A univariate analysis for OS and DFS did not show any significant differences with respect to age, ALL subtype, WBC, stem cell source, use of cranial radiotherapy before transplant and transplant year. A univariate analysis identified the time to transplantation (o12 months), the remission status at transplantation, first transplant and the use of high-dose TBI as prognostic factors for better DFS and OS (Table 4) . Using a multivariate analysis, we demonstrated the favorable impact of remission status at transplant and the use of high-dose TBI on OS (Table 5 ). There is also a trend toward a favorable effect of allo-SCT on OS (HR ¼ 0.57, 95% CI 0.31-1.07, P ¼ 0.082).
Results in CR1 patients Forty-three patients received an allo-HSCT and 23 an auto-HSCT in CR1. Five-year OS, DFS and TRM were 64%, 57%, 20% for the allo-HSCT and 43.5%, 38.6% and 11.7% for the auto-HSCT group (P ¼ NS) (Figure 3) . In univariate analysis, we did not observe prognostic factors for DFS, OS or TRM in the 66 patients transplanted in CR1.
DISCUSSION
To our knowledge, this study reported on the largest number of CNS ALL patients receiving SCT. Our results indicate that allo-HSCT and auto-HSCT are efficient treatments for CNS ALL, with a significant proportion of these patients achieving long-term remission and likely cures. The outcomes of allo-HSCT and auto-HSCT (5-year DFS for 52% and 46% of patients, respectively) are in agreement with a previous study of the GET-LALA group showing a 5-year DFS of 49% and 43% for an auto-HSCT and allo-HSCT group, respectively. 1 This study showed similar OS and DFS in the allo-HSCT group when compared with the auto-HSCT group. A multivariate analysis showed only a trend toward an improved OS in the allo-HSCT group. We can formulate some hypotheses to explain this lack of differences: (i) the sample size of this study was small; (ii) the auto-HSCT group received more frequent cranial irradiation before conditioning, which could have decreased the incidence of CNS relapse; (iii) the benefit of the allo-HSCT could have been offset by a higher mortality rate and (iv) auto-HSCT and allo-HSCT were equally effective in this indication.
We also demonstrated improved DFS and OS with the use of highdose TBI in conditioning, supporting the active, antileukemic efficacy of this regimen. The cranial boost irradiation before conditioning was not associated with a significant reduction of relapse, as previously reported for high-risk ALL. 6 A multivariate analysis confirmed the favorable impact of TBI on OS. However, these results should be taken with cautopn because the vast majority of the patients received highdose TBI and consequently the comparator arm (patients who didn't received high-dose TBI) was too small.
To obtain more consistent comparisons, we decided to repeat the analysis excluding the seven patients who received nonmyeloablative conditioning in the allo-HSCT group. Of the 83 remaining patients, a univariate analysis of DFS and OS showed the same four prognostic factors, including high-dose TBI. A multivariate analysis showed that the only factor associated with OS was high-dose TBI (HR ¼ 0.36, 95% CI 0.17-0.77, P ¼ 0.009). This analysis highlights the importance of high-dose TBI in 
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Relapse/total DFS (95% CI) HSCT for CNS ALL SP Chantepie et al conditioning regimens. In a univariate analysis, after excluding non-myeloablative HSCT, risk factors for increased TRM were similar: allo-HSCT, a time to transplantation 412 months, female gender, absence of CR and a number of transplants 41. A multivariate analysis identified female gender as the sole prognostic factor for higher TRM (Table 6 ), but no longer identified the absence of remission at transplantation. There is still a trend toward higher TRM with the use of allo-HSCT when compared with auto-HSCT (HR ¼ 6.71, 95% CI 0.87-51.85, Po0.07).
The exclusion of patients treated with non-myeloablative conditioning did not change the overall results of the analysis. OS at 5 years post transplant was 53.5% and 37% for the 56 allo-HSCT patients and the 27 auto-HSCT patients, respectively (P ¼ NS).
When limiting the analysis to CR1 patients, we did not find any relevant prognostic factors although survival was better for the allo-HSCT group but without statistical significance. In particular, time to transplantation and the use of high-dose TBI were no longer prognostic factors. There are many possible reasons: (i) TBI and time to transplant are not prognostic factors; (ii) the sample size is too small; (iii) the majority of patients in CR1 have received an early transplant with TBI410 Gy, and consequently, the comparator arm was far too small.
Taking into account that our series included both patients in first CR and patients in more advanced phases, our results compare favorably with those of allo-HSCT for adult high-risk ALL where 40-50% of patients can achieve long-term remission. 7, 8 As previously reported for ALL patients without CNS disease, patients who received transplants early in CR exhibited the best outcome, suggesting that waiting may significantly reduce the chance of long-term survival in cases of adult ALL with CNS disease.
TRM is an important issue for ALL patients. In terms of toxicity, our findings are in line with those of myeloablative allo-HSCT in adult ALL cases.
9,10 ALL patients with CNS involvement at the time of diagnosis have a high rate of TRM (B30% for the allo-HSCT group and o5% for the auto-HSCT group). In the allo-HSCT group, 12 (19%) patients were transplanted in CR2 and 7 (11.1%) in progression or refractory disease. For comparison, in the auto-HSCT group, 85.2% of patients were transplanted in CR1. In patients transplanted in CR1 (69.8%) in the allo-HSCT group, the 5-year TRM was lower (20%), and was close to the reported toxicity in myeloablative conditioning. 8 The most advanced state of patient allografted probably explained the toxicity in the allo-HSCT group as previously reported by the other group. 8 These results indicate that CNS disease is not a prognostic factor for a higher TRM.
The reduction in relapse observed in the allo-HSCT group may be due to the GVL effect. In our study, we cannot demonstrate the effect of the onset of GVHD on survival. OS and DFS were 56%, 50% and 46%, 40% in patients with and without GVHD, respectively (data not shown, P ¼ NS). One explanation may be the low numbers of patients in the allo-HSCT group, resulting in a lack of data on chronic GVHD in eight patients. The onset of GVHD and its GVL effect may overcome the poor prognosis of these high-risk ALL patients, as shown for ALL patients without CNS disease. 7, 8, 11 Therefore, one therapeutic option would be to modulate GVHD in vivo because past studies have shown a significant impact on leukemia relapse with low-dose CYA. 12 The limitations of this study include its retrospective analysis, the low number of patients, the lack of data about DLI, GVH status, the heterogeneity of treatments prior transplantation and possible inherent bias in patients who have been referred for transplantation.
Controlled prospective studies are necessary to validate such an approach. However, because of the rarity of CNS-positive ALL, it is unlikely that prospective or specifically designed studies could be performed in the context of CNS-positive ALL. We really believe in the benefit of the use of high-dose TBI in this population of ALL patients and these data indicate that improving the outcome of ALL with CNS involvement at the time of diagnosis will come with early HSCT in CR and the use of high-dose TBI in conditioning. 
